Clinical trial
Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and…
NCT00060801 · Boehringer Ingelheim, Industry · Terminated
Key facts
| NCT number | NCT00060801 |
|---|---|
| Title | Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients |
| Official title | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult (75 mg, 150 mg) and Pediatric (75 mg) Cystic Fibrosis Patients |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | BIIL 283 BS (Amelubent) |
| Enrollment | 420 |
| Start date | May 1, 2003 |
| Primary completion | Jul 1, 2004 |
| First posted | May 14, 2003 |
| Last update posted | Oct 31, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: